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Introduction: Survivin is an apoptotic inhibitor, involves in regu-
lation of apoptosis and cell cycle progression, and its polymor-
phisms may influence the development and progression of cancer.
This study evaluated the impact of the survivin gene polymorphisms
on survival of non-small cell lung cancer (NSCLC) patients.
Methods: In this case-cohort follow-up study, a total of 568 NSCLC
patients were investigated and 12 single nucleotide polymorphisms
in survivin gene were genotyped by using the Illumina GoldenGate
platform.
Results: During the maximum of 72 months of follow-up, 314
(55.11%) deaths were observed. After adjusting for age, gender, smok-
ing status, histology, stage, surgical operation, and chemotherapy or
radiotherapy status, Cox hazard proportional model suggested that four
single nucleotide polymorphisms had statistically significant impacts
on NSCLC survival (rs3764383, AG/GG versus AA, hazard ratio
[HR]  0.78, 95% confidence interval [CI]: 0.62–0.99; rs8073069,
GG versus CG/CC, HR 1.76, 95% CI: 1.16–2.67; rs4789551, GG
versus AG/AA, HR  2.04, 95% CI: 1.08–3.86; rs1042489, GG
versus AG/AA, HR  1.37, 95% CI: 1.03–1.83). Further combined
analysis showed that the high risk group (3–4 unfavorable loci)
presented a 1.84-fold (95% CI: 1.22–2.77) increased risk compared
with low risk group (0–2 unfavorable loci). Among 185 stage III to
IV patients who received only chemotherapy, only the potentially
functional rs8073069 still had a significantly increased risk on the
prognosis of NSCLC (GG versus CG/CC, HR  2.06, 95% CI:
1.10–3.87).
Conclusions: Our results suggest that polymorphisms in survivin
may be a genetic modifier for NSCLC prognosis in this Chinese
population.
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Non-small cell lung carcinoma (NSCLC) is the leadingcause of cancer death worldwide, and the prognosis of
NSCLC is still poor with a 5-year survival rate of less than
9% in the developing countries.1 The current model by using
information of clinical diagnosis, patient characteristics com-
bined with pathology or stage, cannot accurately predict
patient outcome. To further understand the biology of
NSCLC development and prognosis, the information from
single nucleotide polymorphisms (SNPs) in genes at molec-
ular level is believed to help develop new effective treatment
modalities and predict the prognosis.
Survivin, one member of inhibitors of apoptosis pro-
teins gene family, is involved in regulation of apoptosis, cell
cycle progression, and microtubule stability.2–5 Suvivin has
also been observed to be selectively expressed in cancer cells
but not in normal tissues.5 The overexpression of survivin in
human malignancies is considered to be an important indica-
tor for advanced and chemoresistant disease, and correlates
with more aggressive behavior and poorer prognosis, sug-
gesting that survivin plays a critical role in carcinogenesis,
prognostic, and therapeutic implications.6–10 SNPs of sur-
vivin may influence survivin expression, and further normal
cell apoptosis, as well as aberrant cell cycle-dependent tran-
scription.11 Although several case-control studies have stud-
ied on the variants of survivin,12–15 more efforts should be
performed to evaluate of the prognosis of survivin gene
polymorphisms on NSCLC survival. We hypothesized that
genetic variants in survivin gene might influence the ex-
pression of survivin, and result in chemoresistant and/or
poor prognosis of NSCLC patients. To test the hypothesis,
we selected 12 SNPs in survivin and evaluated the rela-
tionship between these SNPs and prognosis of NSCLC in




The patients’ recruitment and subjects’ characteristics
and clinical features were described previously.16 Briefly, a
total of 568 NSCLC patients who had complete clinical and
follow-up information and adequate DNA samples were pro-
spectively recruited from the Cancer Hospital of Jiangsu
Province and the First Affiliated Hospital of Nanjing Medical
University, Nanjing, China, since July 2003 to April 2008
(see Supplementary Table, http://links.lww.com/JTO/A39).
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The maximum duration of follow-up was 72 months (last
follow-up date: July 2009). Our study was approved by the
Institutional Review Board of Nanjing Medical University.
Selection of Gene Polymorphisms
Polymorphisms in survivin gene were selected by an
approach combining both potentially functional SNPs and
tagging SNPs. The details of selection strategy were pre-
sented elsewhere.16 In brief, potentially functional polymor-
phisms were identified if they are located in the 5-flanking
regions, 5-UTR, 3-UTR and coding regions with amino acid
changes, or have biologic significance according to the pre-
vious studies. Tagging SNPs (tSNP) were chosen from geno-
typed SNPs of CHB (Chinese Han Beijing), based on the
HapMap database (minor allele frequency [MAF] 0.05,
Hardy-Weinberg equilibrium p  0.05 and call rate 90%),
by Haploview 4.1 software. As a result, 12 SNPs (2 poten-
tially functional SNPs and 10 tSNPs) in survivin gene were
finally selected for genotyping and the details of the SNPs
were shown in Table 1.
Genotyping Assay
All 12 SNPs were genotyped by using the Illumina
GoldenGate platform in Taizhou, Jiangsu province, China.
The information on assay conditions, primers and probes is
available on request. Quality control was described in details
in our previous studies.16,17 One of the 12 SNPs was excluded
from further analysis for the call rate less than 95%
(rs2239680) (Table 1).
Statistical Analysis
Fisher’s exact test was used to test the Hardy-Weinberg
equilibrium. Survival time was calculated from the date of
NSCLC diagnosis to the date of patient’s dead or the last date
of follow-up and median survival time (MST) was presented.
If a patient was lost to follow-up or if the study ended before
death, the outcome variable was flagged as censored. Kaplan-
Meier method and Log-rank test were used to compare the
survival time in different subgroups categorized by patient
characteristics, clinical features, and genotypes. Univariate
and multivariate Cox regression models were performed to
estimate the hazard ratio (HR) and their 95% confidence
intervals (CIs), adjusting for age, gender, smoking status,
histology, stage, surgical operation, and chemotherapy or
radiotherapy status. The heterogeneity between subgroups
was assessed with the 2-based Q test.
All analyses were performed using the Statistical Anal-
ysis System software (version 9.1.3; SAS Institute, Cary, NC)
and Stata (version 9.2; Stata Corporation, College Station,
TX). All statistical evaluations were made assuming a two-
sided test with significant level of 0.05, unless stated other-
wise.
RESULTS
Description of Patient Characteristics
Patients’ characteristics and clinical features were described
in Supplemental Table 1 (http://links.lww.com/JTO/A35). In short,
among the 568 patients, 353 (62.2%) patients had an advanced
disease with 221 (38.9%) diagnosed at stage III and 132 (23.2%)
at stage IV. Most of the patients underwent special treatments,
368 (64.8%) underwent surgery and 462 (81.3%) received
chemotherapy or radiotherapy. No significant differences
were observed for the association between NSCLC-specific
survival and patients’ characteristics, except for clinical stage
(Log-rank p  0.001) and surgical operation (Log-rank p 
0.001). Patients of advanced stages or without surgery had
obviously worse prognosis.
Single SNP Analysis
The effects of 11 survivin SNPs included in the final
analysis on NSCLC survival were summarized in Table 2.
There were no significant associations for the 11 SNPs by
performing Log-rank test in three genetic models, except for
rs4789551 (Log-rank p for trend 0.045; GG versus AG/AA
Log-rank p 0.013). However, when using multivariate Cox
hazard proportion model, four SNPs (rs3764383, AG/GG
versus AA, HR  0.78, 95% CI: 0.62–0.99, p  0.043;
rs8073069, GG versus CC, HR  1.80, 95% CI: 1.17–2.78,
TABLE 1. Characteristics of Selected 12 SNPs in Survivin Gene













Survivin/BIRC5 rs3764383 Promoter T AG 0.21 0.23 99.60 0.202 19/198/349
Survivin/BIRC5 rs8073069 Promoter F CG 0.28 0.26 99.80 0.214 39/243/285
Survivin/BIRC5 rs9904341 5 UTR F GC 0.50 0.49 99.80 0.012 124/314/129
Survivin/BIRC5 rs4789551 Intron T AG 0.14 0.09 99.50 0.211 14/126/425
Survivin/BIRC5 rs2515815 Intron T AG 0.50 0.48 99.60 0.018 125/312/129
Survivin/BIRC5 rs11868371 Intron T GC 0.15 0.12 99.80 0.740 11/147/409
Survivin/BIRC5 rs2071214 Glu129Lys T AG 0.21 0.18 99.80 0.078 18/203/346
Survivin/BIRC5 rs2239680 3 UTR T AG 0.50 0.26 22.00 0.000 0/125/0
Survivin/BIRC5 rs1042489 3 UTR T AG 0.44 0.40 99.50 0.126 101/297/167
Survivin/BIRC5 rs2661694 3 UTR T CA 0.21 0.23 99.60 0.131 19/201/346
Survivin/BIRC5 rs1042541 3 UTR T GA 0.35 0.37 99.80 0.033 57/281/229
Survivin/BIRC5 rs1042542 3 UTR T GA 0.34 0.37 99.30 0.003 49/285/230
a Variant homozygote/heterozygote/wild homozygote.
T, tagging SNPs; F, potentially functional SNPs; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.
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TABLE 2. Survivin-Related Polymorphisms and NSCLC Patients Survival
Genotype Patients Deaths MST (Months) Log-Rank p Adjusted HRa (95% CI)
rs3764383
AA 349 199 22.40 1.00 (reference)
AG 198 102 27.80 0.79 (0.62–1.01)
GG 19 9 41.70 0.278 0.67 (0.34–1.33)
AG/GG vs. AA 217/349 111/199 27.80/22.40 0.117 0.78 (0.62–0.99)
rs8073069
CC 285 152 25.90 1.00 (reference)
CG 243 133 25.30 1.05 (0.83–1.33)
GG 39 25 15.80 0.211 1.80 (1.17–2.78)
GG vs. CG/CC 39/528 25/285 15.80/25.90 0.082 1.76 (1.16–2.67)
rs9904341
GG 129 72 23.70 1.00 (reference)
GC 314 169 25.90 0.93 (0.70–1.23)
CC 124 69 22.60 0.377 1.03 (0.73–1.43)
GC/CC vs. GG 438/129 238/72 25.10/23.70 0.259 0.95 (0.73–1.25)
rs4789551
AA 425 226 25.50 1.00 (reference)
AG 126 72 25.30 1.05 (0.80–1.37)
GG 14 10 11.10 0.045 2.07 (1.09–3.91)
GG vs. AG/AA 14/551 10/298 11.10/25.30 0.013 2.04 (1.08–3.86)
rs2515815
AA 129 72 23.70 1.00 (reference)
AG 312 168 25.90 0.93 (0.70–1.23)
GG 125 69 22.60 0.408 1.01 (0.72–1.42)
AG/GG vs. AA 437/129 237/72 25.10/23.70 0.252 0.95 (0.73–1.25)
rs11868371
GG 409 223 25.90 1.00 (reference)
GC 147 80 23.10 1.10 (0.85–1.42)
CC 11 7 21.10 0.548 1.94 (0.91–4.16)
GC/CC vs. GG 158/409 87/223 22.40/25.90 0.883 1.14 (0.88–1.46)
rs2071214
AA 346 195 25.10 1.00 (reference)
AG 203 110 24.00 1.00 (0.79–1.27)
GG 18 6 33.50 0.499 0.51 (0.23–1.16)
AG/GG vs. AA 221/346 116/195 24.30/25.10 0.511 0.96 (0.76–1.20)
rs1042489
AA 167 86 27.80 1.00 (reference)
AG 297 164 25.30 1.22 (0.94–1.59)
GG 101 60 19.10 0.216 1.56 (1.11–2.19)
GG vs. AG/AA 101/464 60/250 19.10/26.20 0.087 1.37 (1.03–1.83)
rs2661694
CC 346 197 22.60 1.00 (reference)
CA 201 104 27.40 0.81 (0.64–1.03)
AA 19 9 41.70 0.358 0.67 (0.34–1.33)
CA/AA vs. CC 220/346 113/197 27.80/22.60 0.168 0.80 (0.63–1.01)
rs1042541
GG 229 124 24.70 1.00 (reference)
GA 281 158 24.30 1.05 (0.83–1.33)
AA 57 28 32.50 0.787 0.73 (0.48–1.10)
GA/AA vs. GG 338/229 186/124 25.30/24.70 0.823 0.98 (0.78–1.23)
rs1042542
GG 230 124 24.70 1.00 (reference)
GA 285 160 24.70 1.05 (0.83–1.33)
AA 49 24 27.70 0.884 0.73 (0.47–1.14)
GA/AA vs. GG 334 184 25.30 0.900 1.00 (0.79–1.25)
(Continued)
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p  0.008; GG versus CG/CC, HR  1.76, 95% CI: 1.16–
2.67, p 0.008; rs4789551, GG versus AA, HR 2.07, 95%
CI: 1.09–3.91, p  0.026, GG versus AG/AA, HR  2.04,
95% CI: 1.08–3.86, p  0.027; rs1042489, GG versus AA,
HR  1.56, 95% CI: 1.11–2.19, p  0.010, GG versus
AG/AA, HR  1.37, 95% CI: 1.03–1.83, p  0.033) showed
significant association with NSCLC survival, after adjusting
for age, gender, smoking status, histology, stage, surgical
operation, and chemotherapy or radiotherapy status. How-
ever, no statistically significant associations were found be-
tween the other seven SNPs and NSCLC survival in this
population.
Further more, to reveal the most effective locus, step-
wise Cox regression model was performed with demographic
characteristics, clinical factors, and the four above referred
SNPs on NSCLC survival. As a result, four variables (stage,
surgical operation, chemotherapy or radiotherapy status, and
SNP rs8073069) were selected into the final regression model
at the 0.05 level for entering and 0.051 for removing
(rs8073069, GG versus CG/CC, HR  1.80, 95% CI: 1.18–
2.73, p  0.006).
Combined and Stratified Analysis
We also put the above four SNPs (rs3764383,
rs8073069, rs4789551, and rs1042489) together to assess the
combined effects on NSCLC survival (Table 2). We found
that the more unfavorable loci were carried, the shorter the
MST was presented (p for trend  0.002). In the dichoto-
mized analysis, high risk patients carrying 3 to 4 unfavorable
loci had an MST of 13.90 months, whereas those low risk
patients with 0 to 2 unfavorable loci had an MST of 25.90
months. In the further multivariate Cox model analysis, high
risk group showed a significantly 1.84-fold (95% CI: 1.22–
2.77) increased risk compared with low risk group. We
further conducted stratified analyses to assess the dichoto-
mized combined effects on NSCLC survival according to
histology, stage (early stage, I–II; advanced stage, III–IV),
surgical operation, and chemo- or radiotherapy status (Table
3). The results showed that patients carrying unfavorable loci
presented a slightly worse prognosis in the subgroups of
female (HR: 3.41, 95% CI: 1.26–9.25), advanced stage (HR:
2.35, 95% CI: 1.48–3.73), ever smokers (HR: 1.94, 95% CI:
1.20–3.14), adenocarcinoma (HR: 2.08, 95% CI: 1.24–3.50),
and without surgery (HR: 2.03, 95% CI: 1.09–3.77). How-
ever, there was no significant heterogeneity between these
subgroups. We then evaluated the multiplicative gene-gene/
gene-environment interactions between the SNPs rs3764383,
rs8073069, rs4789551, rs1042489 and demographic/clinical
factors by using multivariate Cox model. However, no sta-
tistical significant interactions were observed (data not
shown). We also performed haplotype inference using the
phase 2.1 based on the known genotypes of the four SNPs.
However, no statistically significant association between the
haplotypes of these four SNPs in survivin and lung cancer
survival was evident (data not shown).
Subgroup Analysis among Patients with Only
Chemotherapy
To evaluate the effects of the 11 SNPs on lung cancer
survival among stage III to IV patients who treated with
platinum-based agents and without surgical operation, we
further performed a subgroup analysis. Interestingly, the G
allele of rs8073069 had a significantly increased risk (p for
trend: 0.007). In the multivariate analysis, significant risk
effects of rs8073069 existed in all the genetic models (CG
versus CC, HR: 1.42, 95% CI: 1.00–2.02, p  0.049, GG
versus CC, HR: 2.18, 95% CI: 1.13–4.23, p  0.021;
CG/GG versus CC, HR: 1.50, 95% CI: 1.07–2.10, p 
0.018; GG versus CG/CC, HR: 2.06, 95% CI: 1.10–3.87,
p  0.025; Table 4).
DISCUSSION
In this study among Chinese, we investigated the asso-
ciation between genetic polymorphisms of survivin gene and
the prognosis of NSCLC. Among the 12 SNPs examined, 4
SNPs (rs3764383, rs8073069, rs4789551, and rs1042489)
were associated with NSCLC prognosis but only rs8073069
remained in the final stepwise Cox regression model. In the
further subgroup analysis, the patients carrying rs8073069
GG genotype had significantly shorter MST for those re-
ceived only chemoagents treatment. Our findings suggest that
TABLE 2. (Continued)
Genotype Patients Deaths MST (Months) Log-Rank p Adjusted HRa (95% CI)
Combined analysis
0 unfavorable locib 216 110 27.80 1.00 (reference)
1 unfavorable locib 243 136 24.30 1.20 (0.93–1.55)
2 unfavorable locib 61 34 20.90 1.29 (0.87–1.91)
3 unfavorable locib 27 17 17.20 1.99 (1.18–3.36)
4 unfavorable locib 13 9 11.10 2.24 (1.13–4.45)
p for trend 0.002 1.21 (1.07–1.37)
Low risk (0–2) 520 280 25.90 1.00 (reference)
High risk (3–4) 40 26 13.90 1.84 (1.22–2.77)
a Adjusted for age, gender, smoking status, histology, stage, surgical operation, and chemotherapy or radiotherapy status.
b The combined genotypes were dichotomized according to unfavorable loci carried (rs1042489 GG, rs3764383 AA, rs4789551 GG, and rs8073069 GG).
MST, median survival time; HR, hazard ratio, CI, confidence interval.
Bold type indicates significance.
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polymorphisms in survivin gene might be important predic-
tors for lung cancer prognosis and treatment outcome.
Survivin, also known as birc5, is a 16.5-kd protein and
the corresponding gene locates on human chromosome
17q25. Among proteins of the inhibitors of apoptosis protein
family, survivin seems to be selectively expressed in trans-
formed cells and in most human cancers, including
NSCLC.18–22 Survivin has multiple functions including cyto-
protection, inhibition of cell death, and cell-cycle regulation,
especially at the mitotic process stage, and all of which are
associated with cancer cell progression and eventually with
patients’ survival. Growing evidence was accumulated that
the overexpression of survivin was associated with various
human cancers, including NSCLC.12–15,23–31 Recently, an in
vitro study by Karna et al.32 suggested that the decreased
apoptosis caused by overexpression of survivin was the key
point for EM011 mediating antiproliferative and proapoptotic
activity in non-small cell A549 lung cancer cells. Krepela et
al.33 also found that the expression of the survivin gene could
inhibit apoptosis and accelerate tumor cell proliferation to
TABLE 3. Stratified Analysis of Combined Effects of rs1042489, rs3764383, rs4789551, and rs8073069 Genotypes









Total 520/280 40/26 1.84 (1.22–2.77) —
Age 0.930
60 263/141 17/11 1.91 (1.01–3.62)
60 257/139 23/15 1.84 (1.07–3.17)
Gender 0.210
Male 393/215 34/21 1.69 (1.07–2.68)
Female 127/65 6/5 3.41 (1.26–9.25)
Stage 0.130
I-II 199/70 15/5 1.04 (0.40–2.66)
III-IV 321/210 25/21 2.35 (1.48–3.73)
Smoking 0.312
Never 187/102 10/6 1.17 (0.50–2.76)
Ever 333/178 30/20 1.94 (1.20–3.14)
Histology 0.588
Adenocarcinoma 325/174 25/17 2.08 (1.24–3.50)
Squamous cell 167/88 13/8 1.29 (0.61–2.72)
Othersd 28/18 2/1 1.86 (0.21–16.67)
Surgical operation 0.567
None 183/140 13/12 2.03 (1.09–3.77)
Yes 337/40 27/14 1.59 (0.91–2.80)
Chemo- or radiotherapy 0.926
None 92/39 13/7 2.18 (0.91–5.23)
Yes 428/241 27/19 2.08 (1.29–3.35)
a The combined genotypes were dichotomized according to unfavorable loci carried (rs1042489 GG, rs3764383 AA, rs4789551 GG, and rs8073069 GG).
b Adjusted for age, gender, smoking status, histology, stage, surgical operation, and chemotherapy or radiotherapy status.
c Q test for heterogeneity between groups.
d Other carcinomas include large cell, undifferentiated and mixed-cell carcinomas.
NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval.
Bold type indicates significance.











CC 96 71 16.20 1.00
CG 77 63 13.50 1.42 (1.00–2.02) 0.049
GG 12 11 10.30 0.018 2.18 (1.13–4.23) 0.021
CG/GG vs. CC 89/96 74/71 12.30/16.20 0.037 1.50 (1.07–2.10) 0.018
GG vs. CG/CC 12/173 11/134 10.30/14.70 0.019 2.06 (1.10–3.87) 0.025
a Adjusted for age, gender, smoking status, histology, stage.
NSCLC, non-small cell lung cancer; MST, median survival time; HR, hazard ratio; CI, confidence interval.
Bold type indicates significance.
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produce more aggressive carcinomas in lung cancer. Simil-
ary, a follow-up study by Chen et al.34 found that patients
with low survivin expression had significantly longer progres-
sion-free survival and overall survival in NSCLC. A meta-
analysis showed that the expression level of survivin was
correlated with the overall survival of NSCLC patients.35
In our study, two SNPs located in the survivin
promoter region (rs3764383, rs8073069), one SNP in 3
UTR (rs1042489), and one in intron (rs4789551) were
significantly associated with a worse prognosis of NSCLC
patients. Bioinformatics analysis of the 5-flanking region of
the survivin gene showed that there are several cell cycle-
dependent elements (GGCGG), and one cell cycle homology
region (ATTTGAA).36,37 These two SNPs (rs3764383,
rs8073069) in the promoter region may depress survivin
transcription by modifying the binding motif of the cycle-
dependent elements/cycle homology region repressor. There-
fore, survivin acts as an inhibitor of apoptosis that is essential
for eliminating mutated or transformed cells from the body,
and it is biologically plausible that subjects carrying a geno-
type with higher expression of survivin may have decreased
apoptotic capacity to eliminate cells with DNA damage, and
thus may have a shorter survival time and poorer prognosis.
The effects of survivin were more notable in the subgroups of
female, advanced stage, ever smokers through the stratified
analysis. The results demonstrated that worse prognosis was
observed in the above subgroups among the patients who
carried 3 to 4 unfavorable loci. The cumulative effects of
SNPs may further impact the expression of survivin and result
in obvious observations in the subgroups.
Furthermore, Cox regression analysis showed that the
genotype GG of rs8073069 was consistently correlated with
NSCLC prognosis in both the total study subjects and the
subgroup patients with only chemotherapy (HR  1.80, p 
0.008; HR  2.18, p  0.021, respectively). Studies sug-
gested that survivin plays a role in tumor progression and
chemoresistance by inhibiting cell death induced by several
anticancer agents, including paclitaxel, etoposide, and tumor
necrosis factor-a-related apoptosis-inducing ligand.38–41 In
vitro and in vivo studies showed that inhibiting survivin may
reduce tumor growth potential and sensitizes tumor cells to
chemotherapeutic agents, such as paclitaxel, cisplatin, etopo-
side, gamma irradiation, and immunotherapy.42 Biran et al.43
found that by blocking the expression of survivin, combina-
tion therapy with valproic acid (VPA) and farnesylthiosali-
cylic acid might offer a promising therapeutic approach to the
treatment of epithelial tumors. Recently, two reviews about
anticancer therapy summarized that survivin had been pro-
posed as an attractive target for new anticancer interventions
and would play an important role for survivin-targeted cancer
therapy in the future clinical application.44,45
Although a few previous case-control studies fo-
cused on the association between survivin rs9904341
(-31GC) and the susceptibility of cancer,12–15 no signif-
icant association of rs9904341 with lung caner prognosis
was observed in this study population. A possible expla-
nation for the discrepancy may be the different mechanism
in terms of lung cancer susceptibility and prognosis. More-
over, the significant polymorphism rs8073069 was in link-
age disequilibrium with rs9904341 (D’  1.0 and R2 
0.404) in our subjects, suggesting that the role of
rs9904341 may be represented partially by rs8073069.
Further functional studies are warranted to elucidate the
biologic significance of these two SNPs.
In conclusion, our findings suggest that polymorphisms
in survivin may be a genetic modifier for NSCLC prognosis
in this Chinese population, especially for the promoter SNPs
among patients after chemotherapy. However, further expres-
sion or functional studies are warranted to clarify the role of
survivin gene as a prognostic or targeted biomarker for
NSCLC patients.
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